



Testimony of Fanny Mlinarsky on behalf of quadraScope Ventures

Obtaining healthcare is a basic human right and should be guided by physicians and scientific boards, not government bureaucracies.

Risk vs efficacy judgement call is up to the individual. If someone has stage 4 cancer, their risk tolerance may be high. If the therapy in question is preventive, the risk tolerance would likely be low. The ultimate decision should rest with the individual and their medical and scientific team – the authorities they trust.

A state like NH that enables people to receive the medical care they seek would attract clinics, medical research organizations, biotech manufacturing, laboratories for advanced therapies and supporting businesses. Venture funds like my fund, quadraScope Ventures, would preferentially invest in NH businesses knowing that these businesses have low barriers to revenue.

More businesses would move to NH to benefit from expedient access to markets. Medical industry needs lower regulatory barriers to reduce their cost of getting to market. Reducing cost of getting to market would make the treatments more affordable and more available to the people who need them. Lower regulatory barriers would attract more investment because return on investment vs time would increase. More investment would spur innovation and create life-saving medicine for the people who need it.

New Hampshire can greatly benefit from its strategic geography, right next to Boston, worlds biotech capital of the world. With relaxed medical regulations, New Hampshire could attract Boston's top scientific and medical talent to enable its medical industry to flourish.